Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cao, Zhuo ^a   Song, Jia ^a   Wang, Jun ^a   Guo, Xufeng ^a   Yu, Shijie ^a   Dong, Weiguo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OXALIPLATIN; XRCC1 PROTEIN;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DOSE RESPONSE; ETHNICITY; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XRCC1 GENE;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; CISPLATIN; DATABASES, BIBLIOGRAPHIC; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908090534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085357     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global Cancer Statistics. Ca-Cancer J Clin 61: 69-90.
2. Nagasubramanian R, Innocenti F, Ratain MJ (2003) Pharmacogenetics in cancer treatment. Annual Review of Medicine-Selected Topics in the Clinical Sciences 54: 437-452. (Pubitemid 37386406)
3. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Brit J Cancer 90: 8-11. (Pubitemid 38174930)
4. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidem Biomar 13: 801-807. (Pubitemid 38737870)
5. Caldecott KW, Aoufouchi S, Johnson P, Shall S (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 24: 4387-4394. (Pubitemid 26388624)
6. Zhu GY, Lippard SJ (2009) Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatin-DNA Interstrand Cross-Links. Biochemistry-Us 48: 4916-4925.
7. Bernig T, Chanock SJ (2006) Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6: 319-331. (Pubitemid 44174338)
8. Abdel-Rahman SZ, El-Zein RA (2000) The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159: 63-71.
9. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, et al. (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and P-32-DNA adducts in a sample of healthy subjects. Carcinogenesis 22: 1437-1445. (Pubitemid 32898701)
10. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, et al. (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24: 1883-1891. (Pubitemid 46638987)
11. Keam B, Im S, Han S, Ham HS, Kim MA, et al. (2008) Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. Bmc Cancer 8: 148-163.
12. Goekkurt E, Al-Batran S, Hartmann JT, Mogck U, Schuch G, et al. (2009) Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 27: 2863-2873.
13. Huang Z, Hua D, Du X (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemoth Pharm 64: 1001-1007.
14. Liang J, Li Q, Yao R, Lv H, Jiang J, et al. (2010) Association between genetic polymorphisms of ERCCl, XRCCl, GSTPl and survival of advanced. Gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy. Chin J of Oncol 32: 515-519.
15. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, et al. (2010) BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 101: 1247-1254.
16. Won DY, Kim SH, Hur H, Jung H, Jeon HM (2010) Chemotherapeutic Responsibility according to Polymorphism of ERCC1, XRCC1 and GSTP1 in Gastric Cancer Patients Receiving Oxaliplatin Based Chemotherapy. J Korean Surg Soc 78: 350-356.
17. Park SR, Kong S, Nam B, Choi IJ, Kim CG, et al. (2011) CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Brit J Cancer 104: 1126-1134.
18. Zou H, Yang S (2012) Prediction Role of Seven SNPs of DNA Repair Genes for Survival of Gastric Cancer Patients Receiving Chemotherapy. Asian Pac J Cancer P 13: 6187-6190.
19. Ji M, Xu B, Jiang J, Wu J, Li X, et al. (2013) Relationship between Glutathione S-Transferase P1 (GSTP1), X-Ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-Methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer. Onkologie 36: 335-340.
20. Liu Y, Ling Y, Qi Q, Zhang Y, Zhang C, et al. (2013) Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep 7: 1904-1911.
21. Gao C, Chen H, Lu J, Ding J, Li S, et al. (2010) Relationship between polymorphisms of XRCC1 gene and sensitivity to chemotherapy in advanced gastric cancer. Chin J of Clinical Rational Drug Use 3: 4-6.
22. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, et al. (2011) Effect of Genetic Polymorphisms Related to DNA Repair and the Xenobiotic Pathway on the Prognosis and Survival of Gastric Cancer Patients. Anticancer Res. 31: 705-710.
23. Qiu D, Wang F (2009) Polymorphism of XRCC1 Gene influences response to Oxaliplatin-based chemotherapy in patients with advanced gastric cancer. J of Radioimmunology. 22: 630-632.
24. Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437. (Pubitemid 46768164)
25. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214. (Pubitemid 11167383)
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer I 92: 205-216. (Pubitemid 30099779)
28. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. TRIALS 8: 16-25.
29. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, et al. (2011) DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy. Ann Surg Oncol 18: 2688-2698.
30. Liu B, Wei J, Zou Z, Qian X, Nakamura T, et al. (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15: 1049-1053. (Pubitemid 47491460)
31. Wei J, Zhang W, Zou Z, Qian X, Yu L, et al. (2007) Single nucleotide polymorphisms in XRCCl and outcome in gastric cancer patients receiving oxaliplatin based chemotherapy. Chin J Public Health Jul 23: 839-840.
32. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008) How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol 37: 136-146. (Pubitemid 351228622)
33. Bosken CH, Wei QY, Amos CI, Spitz MR (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer I 94: 1091-1099. (Pubitemid 34830729)
34. Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, et al. (2011) DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non-Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy. J Clin Oncol 29: 4121-4128.
35. Lv H, Li Q, Qiu W, Xiang J, Wei H, et al. (2012) Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Pathol Oncol Res 18: 1009-1014.
36. Cui ZG, Yin ZH, Li XL, Wu W, Guan P, et al. (2012) Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. Bmc Cancer 12: 71.
37. Ye FH, Liu ZF, Tan AH, Liao M, Mo ZN, et al. (2013) XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemoth Pharm 71: 733-740.
38. Wu JJ, Liu J, Zhou YH, Ying J, Zou HD, et al. (2012) Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis. Clin Cancer Res 18: 3972-3981.
39. Zintzaras E, Lau J (2008) Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61: 634-645. (Pubitemid 351766746)